[DISCLOSURE] Samil Pharmaceutical (000520) announced on July 29 that it has signed a license agreement with Galmed Pharmaceuticals for the commercialization of Aramchol for the treatment of fatty liver indications including Non-Alcoholic Steato-hepatitis (NASH) in Korea.
Samil will pay Galmed a fee of US$8.08 million for the deal.
Samil will pay Galmed a fee of US$8.08 million for the deal.